drugset / Trial / NCT02634983

QVA Mechanistic Efficacy Study (Receptor Effects, Etc)

NCT02634983

Phase 4 Completed 31 enrolled Novartis Pharmaceuticals
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study was to assess global ventilated lung volume in moderate to severe COPD patients using MRI lung imaging after treatment with QVA149 compared to placebo.

Timeline

Start
2016-06-03
Primary completion
2017-09-26
Completion
2017-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject QVA149 Other / unclassified 50 ug Inhaled
Subject QVA149 Other / unclassified 110 ug Inhaled